Argent BioPharma Secures Funding for Drug Development
Argent BioPharma, a clinical-stage biopharmaceutical company, has successfully closed a capital raise of $4,500,000. This funding will significantly enhance their capacity to pursue innovative treatments aimed at central nervous system disorders and immune-related conditions through their advanced nano-medicine technologies.
Details of the Capital Raise
The successful capital raise involved the subscription of 5,625,000 units, each priced at $0.80. These units will include two fully paid ordinary shares, alongside one free-attaching warrant that is exercisable at $0.55, with an expiry three years from the issuance date.
Tranche Distribution
The capital placement will occur in two tranches. The first tranche consists of 5,000,000 placement shares and 2,500,000 warrants which will be issued immediately under existing placement capacity guidelines. The second tranche will follow, requiring shareholder approval to issue a further 6,250,000 shares and 3,125,000 warrants.
Impact of the Raise on Development Pipeline
The proceeds from this capital raise will primarily support the advancement of Argent BioPharma's extensive drug development pipeline. Notably, the company is focusing on progressing its lead candidate, CannEpil, through planned clinical studies aimed at addressing unmet medical needs.
Strategic Review and Future Plans
In addition to expanding their funding, Argent BioPharma is engaging in a thorough review of their operational and administrative functions. This analysis comes on the heels of their recent delisting from certain stock exchanges and focuses on paving the path toward a potential listing in the US market.
Role of Corporate Advisor
Sputnik Enterprises Ltd acted as the corporate advisor throughout this placement process. They will receive a cash fee of 5% of the proceeds along with warrants, pending shareholder approval.
Company Overview
Argent BioPharma Limited is recognized for its pioneering work in the biopharmaceutical sector, specifically within neuroimmunology. The company is leveraging innovative technologies to develop advanced nano-medicines that address serious health issues affecting the central nervous system. Their promising pipeline includes projects like CannEpil, CogniCann, and CimetrA, which are all directed toward treating complex, unresolved health challenges.
Contact Information
If you would like more information about Argent BioPharma or the recent funding, feel free to reach out to their executive team:
Roby Zomer
CEO & Managing Director
Phone: +61 8 6555 2950
Email: info@argentbiopharma.com
Rowan Harland
Company Secretary
Phone: +61 8 6555 2950
Email: info@argentbiopharma.co.uk
Frequently Asked Questions
1. What is Argent BioPharma known for?
Argent BioPharma is a biopharmaceutical company focused on developing treatments for central nervous system and immune-related disorders.
2. How much funding did Argent BioPharma raise?
The company raised $4,500,000 to further their drug development initiatives.
3. What are the main uses of the raised funds?
The funds will support the advancement of their drug development pipeline, particularly focusing on CannEpil and other candidates.
4. What is the structure of the capital raise?
The raise consists of two tranches including shares and warrants, with the first tranche set for immediate issuance.
5. Who were the advisors for this capital raise?
Sputnik Enterprises Ltd served as the corporate advisor and will receive a cash fee along with warrants for their services.
